NEW YORK, April 15, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ ) announced that trading of Aduro Biotech, Inc. (Nasdaq: ADRO ) commenced on The Nasdaq Stock Market on April 15, 2015.
Aduro is a clinical-stage cancer immuno-oncology company. The company’s lead candidate – an immunotherapy regimen combining Aduro’s proprietary CRS-207 with GVAX Pancreas – is in Phase 2b clinical trials targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/Attachm...92e593f21f
“Since its founding, Aduro has focused on identifying new and innovative treatments for cancer,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “We are pleased to welcome Aduro to our family of listed companies and we look forward to supporting its growth and success in the future.”
By listing with Nasdaq, Aduro joins some of the world’s largest and most revolutionary healthcare companies. Nasdaq is the exchange of choice to 94 percent of healthcare companies listed in the U.S. Markets year to date.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Aduro Biotech, Inc. (Nasdaq: ADRO)
Aduro Biotech, Inc. is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro’s lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using cyclic-di-nucleotide (CDN) synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.aduro.com .
About Nasdaq:
Nasdaq (Nasdaq: NDAQ ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $9.1 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.business.nasdaq.com .
The photo is also available via AP PhotoExpress.
NDAQG
MEDIA RELATIONS CONTACT: Will Briganti (646) 441-5012 william.briganti@nasdaq.com Christine Barna (646) 441-5310 Christine.Barna@nasdaq.com
